AstraZeneca Downgraded by HSBC as Wainua Trial Miss Clouds Near-Term Outlook (AZN)

Broker Cuts Rating Following Clinical Disappointment

AstraZeneca (LSE:AZN) came under pressure on Monday after HSBC lowered its recommendation on the pharmaceutical giant to Hold from Buy and reduced its price target from 16,500p to 13,750p following the failure of the Phase 3 Wainua study to achieve its primary endpoint.

“Wainua setback impairs our bull case, given the more difficult catalyst path ahead,” HSBC analyst Rajesh Kumar said.

Shares fell 1.3% in London trading, while the company’s U.S.-listed stock declined 1.5% in premarket dealings.

Delayed Growth Catalysts Shift the Risk Profile

HSBC noted that its previous bullish stance had been supported by expectations for the CARDIO-TTR programme, which it believes represents a market opportunity worth more than US$5 billion.

Although the broker still sees a route to annual peak revenue above US$80 billion by 2030, it believes that outlook now relies on a series of higher-risk clinical milestones that are not expected to materialise before 2027.

Focus Moves to SERENA-4 and AVANZAR

The investment bank also expressed caution over AstraZeneca’s next major clinical updates, particularly the SERENA-4 and AVANZAR studies due in the second half of 2026.

HSBC said its own analysis leaves it “rather uncomfortable” about the prospects for both programmes.

Kumar also warned that another string of unsuccessful trial outcomes could damage confidence in the company’s research engine.

“if three trials fail in a sequence, the widely held view of Astra’s market-leading R&D platform might lose its shine,” he said.

HSBC Sees Limited Upside in the Near Term

According to HSBC, weaker-than-expected results from the remaining 2026 clinical catalysts could intensify concerns over AstraZeneca’s ability to replace revenue lost through major patent expiries expected in the early 2030s.

The broker believes this could restrict further gains in the shares over the next six to nine months, leaving investors increasingly dependent on a stronger pipeline of catalysts in 2027.

“We downgrade the stock to a Hold rating (from Buy) as we no longer find the risk-reward balance attractive, particularly with the remaining catalyst path for 2026 (SERENA 4, AVANZAR) skewed to downside risks,” Kumar concluded.